

Marzia Varettoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1102793/publications.pdf>

Version: 2024-02-01

158
papers

5,017
citations

117453

34
h-index

98622

67
g-index

158
all docs

158
docs citations

158
times ranked

5544
citing authors

#	ARTICLE	IF	CITATIONS
1	Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III INNOVATE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 52-62.	0.8	62
2	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340.	0.8	3
3	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	3
4	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527.	0.8	4
5	Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	8
6	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	3.3	17
7	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	1.1	5
8	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	2.0	10
9	Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN. <i>Leukemia and Lymphoma</i> , 2021, 62, 1782-1785.	0.6	0
10	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	0.8	8
11	MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. <i>Diagnostics</i> , 2021, 11, 779.	1.3	14
12	Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2021, 96, E210-E214.	2.0	7
13	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	2.0	8
14	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab+bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	2.0	3
15	Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1643-1649.	0.9	1
16	Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting. <i>Leukemia and Lymphoma</i> , 2021, 62, 3311-3312.	0.6	0
17	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	0.8	9
18	Prognostic impact of somatic mutations on time to first treatment: Results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E404-E408.	2.0	0

#	ARTICLE	IF	CITATIONS
19	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	3.3	57
20	Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study. <i>Blood</i> , 2021, 138, 134-134.	0.6	3
21	Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 48-48.	0.6	2
22	Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study. <i>Blood</i> , 2021, 138, 2641-2641.	0.6	0
23	Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi. <i>Frontiers in Oncology</i> , 2021, 11, 789891.	1.3	5
24	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	1.2	11
25	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	2.2	96
26	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis. <i>Hematological Oncology</i> , 2020, 38, 689-697.	0.8	7
27	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, 901-908.	1.2	17
28	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , 2020, 95, 1473-1478.	2.0	7
29	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	2.8	7
30	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	2.5	57
31	Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis. <i>Blood</i> , 2020, 135, 293-296.	0.6	27
32	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. <i>Blood</i> , 2020, 136, 763-766.	0.6	33
33	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
34	Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88^{WT}) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20056-e20056.	0.8	4
35	Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial. <i>Blood</i> , 2020, 136, 29-30.	0.6	16
36	IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY. <i>Hematological Oncology</i> , 2019, 37, 183-184.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. <i>American Journal of Hematology</i> , 2019, 94, 1193-1199.	2.0	18
38	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019, 134, 798-801.	0.6	53
39	A risk stratification model based on the initial concentration of the serum monoclonal protein and <i>MYD88</i> mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2019, 187, 441-446.	1.2	13
40	PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY. <i>Hematological Oncology</i> , 2019, 37, 235-237.	0.8	0
41	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Leukemia</i> , 2019, 33, 2654-2661.	3.3	53
42	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , 2019, 37, 160-167.	0.8	15
43	Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. <i>Hematological Oncology</i> , 2019, 37, 117-128.	0.8	15
44	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	0.6	69
45	Impact of Serum Immunoglobulin Subsets and Levels on Chronic Lymphocytic Leukemia Natural History: A Retrospective Multicentric Italian Experience. <i>Blood</i> , 2019, 134, 3026-3026.	0.6	1
46	Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study. <i>Blood</i> , 2019, 134, 1539-1539.	0.6	0
47	Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab. <i>Blood</i> , 2019, 134, 5485-5485.	0.6	1
48	Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis. <i>Blood</i> , 2019, 134, 1502-1502.	0.6	0
49	Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE. <i>Blood</i> , 2019, 134, 5495-5495.	0.6	1
50	External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study. <i>Blood</i> , 2019, 134, 4308-4308.	0.6	0
51	<i>MYD88</i> mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in <i>CXCR4</i> . <i>Haematologica</i> , 2018, 103, e408-e411.	1.7	30
52	A revised international prognostic score system for Waldenström's macroglobulinemia. <i>Annals of Oncology</i> , 2018, 29, viii359.	0.6	0
53	Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients. <i>Blood</i> , 2018, 132, 1607-1607.	0.6	2
54	Light Chain Amyloidosis and Non-Hodgkin's Lymphomas: A Peculiar Association with Distinct Clinical Features and Outcome. <i>Blood</i> , 2018, 132, 2026-2026.	0.6	9

#	ARTICLE	IF	CITATIONS
55	Ibrutinib for the Treatment of Bing-Neel Syndrome. <i>Blood</i> , 2018, 132, 1609-1609.	0.6	2
56	Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2017, 35, 296-302.	0.8	23
57	Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2017, 102, 2077-2085.	1.7	90
58	The possible role of burden of therapy on the risk of myeloma extramedullary spread. <i>Annals of Hematology</i> , 2017, 96, 73-80.	0.8	34
59	CD38, BCL2, PD1, and PD-L1 expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?. <i>American Journal of Hematology</i> , 2017, 92, E1-E2.	2.0	33
60	Bing-Neel Syndrome: illustrative cases and comprehensive review of the literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017061.	0.5	17
61	Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. <i>British Journal of Haematology</i> , 2016, 172, 709-715.	1.2	87
62	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 175, 77-86.	1.2	61
63	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 172, 735-744.	1.2	122
64	Targeted Next Generation Sequencing Identifies Novel Genetic Mutations in Patients with Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma or IgM-Monoclonal Gammopathies of Undetermined Significance. <i>Blood</i> , 2016, 128, 2928-2928.	0.6	2
65	Autologous stem cell transplantation with <i>in vivo</i> purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 230-234.	2.0	9
66	Successful treatment with rituximab and bendamustine in a patient with newly diagnosed Waldenström's Macroglobulinemia complicated by Bing-Neel syndrome. <i>American Journal of Hematology</i> , 2015, 90, E152-3.	2.0	16
67	Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2637-2642.	0.6	55
68	Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. <i>British Journal of Haematology</i> , 2015, 168, 301-302.	1.2	9
69	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	13.9	281
70	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. <i>Haematologica</i> , 2015, 100, 246-252.	1.7	73
71	The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. <i>Blood</i> , 2015, 126, 1486-1486.	0.6	1
72	Indolent Lymphomas: Follicular Lymphoma, HVC-Associated Marginal Zone B-Cell Lymphoma, and Waldenstrom's Macroglobulinemia. , 2015, , 245-252.		0

#	ARTICLE	IF	CITATIONS
73	Long Term Toxicity and Follow-up of Waldenström's Macroglobulinemia Patients after Salvage Treatment with Fludarabine Cyclophosphamide Rituximab or Bendamustine and Rituximab. <i>Blood</i> , 2015, 126, 3958-3958.	0.6	0
74	Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. <i>Blood</i> , 2015, 126, 5084-5084.	0.6	0
75	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133
76	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014, 124, 150-150.	0.6	4
77	Bendamustine and Rituximab Combination Is Safe and Effective As Salvage Regimen in Waldenström's Macroglobulinemia. <i>Blood</i> , 2014, 124, 3072-3072.	0.6	0
78	Associated Cancers in Waldenström Macroglobulinemia: Clues for Common Genetic Predisposition. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 700-703.	0.2	15
79	Monoclonal gammopathy of undetermined significance: a new proposal of workup. <i>European Journal of Haematology</i> , 2013, 91, 356-360.	1.1	24
80	Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 231-234.	0.2	24
81	Microarray Demonstrates Different Gene Expression Profiling Signatures Between Waldenström Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 208-210.	0.2	10
82	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms. <i>Blood</i> , 2013, 121, 2522-2528.	0.6	290
83	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. <i>Blood</i> , 2013, 121, 2051-2058.	0.6	368
84	Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. <i>Leukemia and Lymphoma</i> , 2013, 54, 2485-2489.	0.6	31
85	MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2013, 122, 2284-2285.	0.6	56
86	High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents. <i>Blood</i> , 2013, 122, 1896-1896.	0.6	1
87	Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The "Rete Ematologica Lombarda/Hematology Network Of Lombardia Region". <i>Blood</i> , 2013, 122, 3003-3003.	0.6	1
88	Risk of second cancers in Waldenström macroglobulinemia. <i>Annals of Oncology</i> , 2012, 23, 411-415.	0.6	50
89	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. <i>Blood</i> , 2012, 119, 188-191.	0.6	150
90	Fludarabine plus cyclophosphamide and rituximab in Waldenström macroglobulinemia. <i>Cancer</i> , 2012, 118, 434-443.	2.0	97

#	ARTICLE	IF	CITATIONS
91	Clinical Significance of Tumor-Associated Macrophages in Early-Stage Hodgkin's Lymphoma.. Blood, 2012, 120, 2638-2638.	0.6	0
92	Hierarchical Clustering of B-Cell Receptor Structures in Splenic Marginal Zone Lymphoma. Blood, 2012, 120, 1585-1585.	0.6	0
93	Microarray Identifies Different Molecular Signatures of Waldenstrom Macroglobulinemia (WM) Compared to IgM Monoclonal Gammopathy of Undetermined Significance (IgMMGUS). Blood, 2012, 120, 3495-3495.	0.6	0
94	Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenstrom Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms.. Blood, 2012, 120, 2667-2667.	0.6	1
95	Factors Predicting Transformation of Asymptomatic IgM Monoclonal Gammopathy. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 77-79.	0.2	11
96	Distinctive Clinical and Histological Features of Waldenstrom's Macroglobulinemia and Splenic Marginal Zone Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 103-105.	0.2	22
97	The Impact of Advanced Age According to IPSSWM Cut-Off on the Outcome of Symptomatic and Asymptomatic Waldenstrom's Macroglobulinemia at Diagnosis. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 124-126.	0.2	11
98	The BRAF V600E Mutation in Hairy Cell Leukemia and Other Mature B-Cell Neoplasms. Blood, 2011, 118, 262-262.	0.6	1
99	Clues to the Pathogenesis of Waldenstrom Macroglobulinemia and Other Monoclonal IgM Disorders Provided by the Analysis of Immunoglobulin Heavy Chain Gene Rearrangement and Clustering of B-Cell Receptors,. Blood, 2011, 118, 3680-3680.	0.6	33
100	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica, 2010, 95, 1792-1796.	1.7	91
101	Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance. Medicine (United States), 2010, 89, 211-216.	0.4	16
102	Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. European Journal of Haematology, 2010, 85, 405-415.	1.1	30
103	Bortezomib-induced peripheral neuropathy in multiple myeloma: A comparison between previously treated and untreated patients. Leukemia Research, 2010, 34, 471-474.	0.4	75
104	Emergent Thelper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain. British Journal of Haematology, 2010, 149, 916-918.	1.2	28
105	Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma. Leukemia and Lymphoma, 2010, 51, 236-242.	0.6	19
106	Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology, 2010, 21, 325-330.	0.6	386
107	Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS. Blood, 2010, 116, 3037-3037.	0.6	0
108	Immunoglobulin Heavy Chain (IGH) Gene Rearrangement In Waldenstrom Macroglobulinemia and Other Monoclonal IgM Disorders. Blood, 2010, 116, 4139-4139.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients. <i>European Journal of Haematology</i> , 2009, 82, 240-241.	1.1	6
110	Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived. <i>European Journal of Haematology</i> , 2009, 83, 449-454.	1.1	15
111	A striking response to bortezomib in a patient with pleural localization of multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 577-578.	0.4	5
112	Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. <i>Leukemia Research</i> , 2009, 33, e145-e149.	0.4	11
113	Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 42, 286-291.	0.6	30
114	Risk of Second Cancers in Waldenstrom Macroglobulinemia: a Population-Based Study From Northern Italy.. <i>Blood</i> , 2009, 114, 3951-3951.	0.6	1
115	Evaluation of the Impact of Three Different Pre-Transplant Strategies On the Outcome of Myeloma Patients Candidates to High-Dose Therapy.. <i>Blood</i> , 2009, 114, 1223-1223.	0.6	0
116	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. <i>Blood</i> , 2009, 114, 760-760.	0.6	0
117	Clinical and Biological Implications of Hepatitis C Virus Positivity in Waldenstrom's Macroglobulinemia Patients.. <i>Blood</i> , 2009, 114, 2934-2934.	0.6	1
118	Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas. <i>Leukemia Research</i> , 2008, 32, 841-843.	0.4	8
119	Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. <i>Leukemia Research</i> , 2008, 32, 1085-1090.	0.4	3
120	DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. <i>Transfusion</i> , 2008, 48, 857-860.	0.8	11
121	Immune-mediated neuropathies in myeloma patients treated with bortezomib. <i>Clinical Neurophysiology</i> , 2008, 119, 2507-2512.	0.7	88
122	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. <i>Haematologica</i> , 2008, 93, 1645-1651.	1.7	241
123	Infiltration of the Spinal Cord in a Patient With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 4207-4209.	0.8	9
124	Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires.. <i>Blood</i> , 2008, 112, 1775-1775.	0.6	1
125	Changing Pattern of Presentation in Monoclonal Gammopathy of Undetermined Significance: A Study on 1400 Cases. <i>Blood</i> , 2008, 112, 2706-2706.	0.6	0
126	Results of a Phase II Multicenter Study of Immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Symptomatic Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2008, 112, 3692-3692.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Rapid Response to High-Dose Steroids of Severe Bortezomib-Related Pulmonary Complication in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3380-3381.	0.8	36
128	The Impact of New Emerging Drugs in the Treatment of Multiple Myeloma: Is there Still a Role for PBSC Transplantation?. <i>Current Stem Cell Research and Therapy</i> , 2007, 2, 1-11.	0.6	5
129	A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. <i>Leukemia</i> , 2007, 21, 1545-1548.	3.3	98
130	Late onset of bortezomib-associated cutaneous reaction following herpes zoster. <i>Annals of Hematology</i> , 2007, 86, 301-302.	0.8	9
131	Severe intestinal vasculitis in a patient under treatment with bortezomib. <i>Annals of Hematology</i> , 2007, 86, 923-924.	0.8	7
132	Bortezomib with High-Dose Dexamethasone as First Line Therapy in Patients with Multiple Myeloma Candidates to High-Dose Therapy.. <i>Blood</i> , 2007, 110, 3595-3595.	0.6	8
133	Has the Incidence of Extramedullary Disease Changed with the New Therapeutic Approaches? Analysis of a Cohort of 965 Multiple Myeloma (MM) Patients (pts).. <i>Blood</i> , 2007, 110, 4749-4749.	0.6	0
134	Changes in multiple myeloma epidemiology in the last thirty years: A single centre experience. <i>European Journal of Cancer</i> , 2006, 42, 396-402.	1.3	10
135	Thrombomodulin levels are not modified during thalidomide treatment. <i>European Journal of Haematology</i> , 2006, 77, 453-454.	1.1	9
136	Bisphosphonates and Osteonecrosis of the Jaw: Advantages of a New Schedule.. <i>Blood</i> , 2006, 108, 3590-3590.	0.6	5
137	Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection. <i>Leukemia Research</i> , 2005, 29, 159-163.	0.4	6
138	Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2005, 36, 951-954.	1.3	9
139	Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma. <i>Cancer</i> , 2005, 104, 118-125.	2.0	61
140	Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma. <i>Oncology</i> , 2005, 68, 146-153.	0.9	12
141	Clinical Characteristics and Outcome of Immunoglobulin M-Related Disorders. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 261-264.	2.1	26
142	Prognostic Factors for Transformation in Asymptomatic Immunoglobulin M Monoclonal Gammopathies. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 265-269.	2.1	12
143	The Role of Whole-Body Magnetic Resonance Imaging in the Staging and Follow-Up of Bone Disease in Multiple Myeloma.. <i>Blood</i> , 2005, 106, 5063-5063.	0.6	0
144	The Role of Stromal Cells in Multiple Myeloma: Actors or Spectators?.. <i>Blood</i> , 2005, 106, 2506-2506.	0.6	7

#	ARTICLE	IF	CITATIONS
145	Modification of Cytokine Levels and CD34+ Stem Cell Adhesion Molecules during Mobilization in Multiple Myeloma (MM) Patients.. Blood, 2005, 106, 5068-5068.	0.6	0
146	Normal-looking skin in oncohaematological patients after allogeneic bone marrow transplantation is not normal. British Journal of Dermatology, 2004, 151, 579-586.	1.4	16
147	Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplantation, 2004, 34, 1039-1045.	1.3	9
148	Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Leukemia, 2004, 18, 1555-1557.	3.3	10
149	Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia, 2004, 18, 1512-1517.	3.3	50
150	Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Annals of Hematology, 2004, 83, 588-91.	0.8	64
151	First episode of acute hemolysis due to G6PD deficiency in a middle-aged woman and transmission of the enzymatic defect through bone marrow transplant. Haematologica, 2004, 89, ECR04.	1.7	2
152	Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy. Seminars in Oncology, 2003, 30, 172-177.	0.8	21
153	Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant. Annals of Hematology, 2001, 80, 521-524.	0.8	8
154	Flexural erythematous eruption following autologous peripheral blood stem cell transplantation: a study of four cases.. British Journal of Dermatology, 2001, 145, 490-495.	1.4	9
155	Flexural erythematous eruption following autologous peripheral blood stem cell transplantation: a study of four cases. British Journal of Dermatology, 2001, 145, 490-495.	1.4	1
156	Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplantation, 2000, 25, 309-313.	1.3	63
157	High incidence of symptomatic cytomegalovirus infection in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Blood, 2000, 95, 4016-8.	0.6	0
158	Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. Bone Marrow Transplantation, 1999, 23, 533-537.	1.3	130